Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Short-term Investments (2020 - 2026)

Tango Therapeutics has reported Short-term Investments over the past 6 years, most recently at $400000.0 for Q4 2025.

  • For Q4 2025, Short-term Investments fell 99.79% year-over-year to $400000.0; the TTM value through Dec 2025 reached $400000.0, down 99.79%, while the annual FY2025 figure was $400000.0, 99.79% down from the prior year.
  • Short-term Investments for Q4 2025 was $400000.0 at Tango Therapeutics, down from $94.5 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $350.0 million in Q1 2022 and troughed at $400000.0 in Q4 2025.
  • A 5-year average of $128.8 million and a median of $47.7 million in 2023 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: skyrocketed 31505.72% in 2024 and later tumbled 99.85% in 2025.
  • Year by year, Short-term Investments stood at $567000.0 in 2021, then changed by 0.0% to $567000.0 in 2022, then soared by 58.73% to $900000.0 in 2023, then soared by 20831.89% to $188.4 million in 2024, then crashed by 99.79% to $400000.0 in 2025.
  • Business Quant data shows Short-term Investments for TNGX at $400000.0 in Q4 2025, $94.5 million in Q3 2025, and $428000.0 in Q2 2025.